CL2007002606A1 - Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e - Google Patents

Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e

Info

Publication number
CL2007002606A1
CL2007002606A1 CL200702606A CL2007002606A CL2007002606A1 CL 2007002606 A1 CL2007002606 A1 CL 2007002606A1 CL 200702606 A CL200702606 A CL 200702606A CL 2007002606 A CL2007002606 A CL 2007002606A CL 2007002606 A1 CL2007002606 A1 CL 2007002606A1
Authority
CL
Chile
Prior art keywords
acid
halobenzarilar
echrolid
earrollaroar
cianobenzoic
Prior art date
Application number
CL200702606A
Other languages
English (en)
Spanish (es)
Inventor
G Almstead Peter Seongwoo Neil
Original Assignee
Ptc Therapeutics Inc Soc Organ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc Soc Organ filed Critical Ptc Therapeutics Inc Soc Organ
Publication of CL2007002606A1 publication Critical patent/CL2007002606A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL200702606A 2006-09-08 2007-09-07 Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e CL2007002606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
CL2007002606A1 true CL2007002606A1 (es) 2008-04-18

Family

ID=38935880

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702606A CL2007002606A1 (es) 2006-09-08 2007-09-07 Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e

Country Status (24)

Country Link
US (2) US7678922B2 (enExample)
EP (1) EP2059513B1 (enExample)
JP (2) JP5955494B2 (enExample)
KR (1) KR101466368B1 (enExample)
CN (1) CN101535284B (enExample)
AR (3) AR062715A1 (enExample)
AU (1) AU2007292915B2 (enExample)
BR (1) BRPI0716996B8 (enExample)
CA (2) CA2662749C (enExample)
CL (1) CL2007002606A1 (enExample)
DK (1) DK2059513T3 (enExample)
ES (1) ES2404348T3 (enExample)
IL (1) IL197445A (enExample)
MX (1) MX2009002439A (enExample)
MY (1) MY148598A (enExample)
NZ (2) NZ598012A (enExample)
PE (2) PE20080771A1 (enExample)
PL (1) PL2059513T3 (enExample)
PT (1) PT2059513E (enExample)
RU (1) RU2495030C2 (enExample)
TW (1) TWI482761B (enExample)
UA (1) UA99265C2 (enExample)
WO (1) WO2008030570A1 (enExample)
ZA (1) ZA200901782B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2910551T3 (pl) 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PT2402002T (pt) 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
CA2647903C (en) 2006-03-30 2016-12-13 Ptc Therapeutics, Inc. Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2008030570A1 (en) * 2006-09-08 2008-03-13 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
SI2076501T1 (sl) * 2006-09-25 2016-05-31 Ptc Therapeutics, Inc. Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline
ES2538359T3 (es) 2006-10-12 2015-06-19 Ptc Therapeutics, Inc. Métodos para administrar un 1,2,4-oxadiazol activo por vía oral para terapia de supresión de mutación sin sentido
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
MX2018005361A (es) 2015-10-30 2018-06-07 Ptc Therapeutics Inc Metodos para tratar epilepsia.
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
EA202192767A1 (ru) 2019-04-10 2021-12-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
CN114920667B (zh) * 2022-06-30 2024-06-21 湖南大学 一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2449544A1 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
US20040132726A1 (en) * 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
PL2910551T3 (pl) * 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
PT2402002T (pt) * 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
WO2008030570A1 (en) * 2006-09-08 2008-03-13 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Also Published As

Publication number Publication date
PL2059513T3 (pl) 2013-06-28
WO2008030570A1 (en) 2008-03-13
UA99265C2 (ru) 2012-08-10
TWI482761B (zh) 2015-05-01
DK2059513T3 (da) 2013-05-06
ZA200901782B (en) 2010-06-30
AR062715A1 (es) 2008-11-26
CA2662749A1 (en) 2008-03-13
US8367841B2 (en) 2013-02-05
JP2010502715A (ja) 2010-01-28
CA2842625C (en) 2016-07-12
RU2495030C2 (ru) 2013-10-10
AR118922A2 (es) 2021-11-10
EP2059513B1 (en) 2013-01-23
EP2059513A1 (en) 2009-05-20
PT2059513E (pt) 2013-04-30
BRPI0716996A2 (pt) 2013-10-08
CA2842625A1 (en) 2008-03-13
IL197445A (en) 2014-01-30
AU2007292915A1 (en) 2008-03-13
TW200823180A (en) 2008-06-01
PE20080771A1 (es) 2008-06-13
ES2404348T3 (es) 2013-05-27
AU2007292915B2 (en) 2012-07-26
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
US20080139818A1 (en) 2008-06-12
NZ598012A (en) 2013-08-30
JP5955494B2 (ja) 2016-07-20
MY148598A (en) 2013-05-15
US7678922B2 (en) 2010-03-16
CN101535284A (zh) 2009-09-16
US20100063297A1 (en) 2010-03-11
KR101466368B1 (ko) 2014-11-27
MX2009002439A (es) 2009-03-27
HK1134094A1 (en) 2010-04-16
NZ575511A (en) 2012-02-24
RU2009113019A (ru) 2010-10-20
CA2662749C (en) 2015-01-20
PE20120669A1 (es) 2012-06-01
JP2014193896A (ja) 2014-10-09
CN101535284B (zh) 2014-12-10
BRPI0716996B8 (pt) 2021-05-25
KR20090054464A (ko) 2009-05-29
IL197445A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CL2007002606A1 (es) Proceso para preparar acido de 1,2,4-oxadiazol benzoico o una sal farmaceuticamente aceptable de este que comprende hacer reaccionar un metil ester de acido cianobenzoico con hidroxilamina, acilar con cloruro de halobenzoilo, condensar e hidrolizar e
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
BRPI0719896A2 (pt) Processo para a preparação de alcanolamidas de ácidos graxos
BRPI0911759A2 (pt) microorganismo para a produção de ácido metacrílico
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
NO2015014I1 (no) Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
CL2008002417A1 (es) Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria
BRPI0812807A2 (pt) Método para a produção de um medicamento que contem tadafila
CL2007003177A1 (es) Composicion acuosa curable que comprende un aducto de polimero de carbohidrato y agente de entrecruzamiento multifuncional seleccionado entre acido polibasico monomero, su sal, anhidrido y mezclas; metodo para formar composicion acuosa curable; produ
BRPI1006679A2 (pt) "processo para a preparação de um composto de estireno halogenado"
BRPI1007619A2 (pt) "sistema para prevenção de quedas adequado para ser usado por um usuário e métoddo de operação de um sistema para prevenção de quedas que seja usado pelo usuário"
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
FI20055568A0 (fi) Menetelmä karboksyylihappoesteriseoksien valmistamiseksi ja niiden käyttö
BRPI0821656A2 (pt) Processo para a geração de uma massa em fusão de aço contendo até 30% de manganês
BRPI0915365A2 (pt) Processo para a preparação de 2-triflúor-metil-5-alquil-piridinas substituídas na posição 1
CO6410282A2 (es) Formulaciones orales sólidas de una pirido-pirimidinona
BRPI0808173A2 (pt) método para a produção de cloreto de ácido carboxílico.
DK1910267T3 (da) Fremgangsmåde til fremstilling af carboxylsyrealkylestere
IL212603A (en) A thioester containing and at least one esterase inhibitor, a process for increasing the bioavailability of the theaster by this hut, a pharmacy containing this hut, and a hut containing kit
BRPI1012007A2 (pt) "método para a preparação de ácido 2-ceto-carboxílico"
IL199013A0 (en) Compositions containing an agent which increases production of 15-deoxy-prostaglandin j2 for treating diseases associated with the prostaglandin/cyclooxygenase metabolic pathway
EP2080751A4 (en) CARBON ACID DERIVATIVE
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
BRPI0811380A2 (pt) "processo para a preparação de ácido carboxílico purificado"
CL2007002442A1 (es) Uso de un compuesto analogo de lipoxina a4, su estereoisomero individual, una mezcla de estereoisomeros, o una mezcla racemica de estereoisomeros o como un clatrato de ciclodextrina de este, o como una sal farmaceuticamente aceptable de este, para tr